Management of myelofibrosis: A survey of current practice in the United Kingdom

Journal of Clinical Pathology

Volumn 65, Issue 12, 2012, Pages 1124-1127

  Qureshi, Moosa Rashid ^a   MacLean, Cathy ^b   McMullin, Mary Frances ^c   Harrison, Claire ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSULTATION; HEALTH SURVEY; HUMAN; MYELOFIBROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; UNITED KINGDOM;

GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; INTERNET; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY MYELOFIBROSIS;

EID: 84870063728     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201056     Document Type: Article

References (12)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
2. Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011;35:12-13.
3. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76. (Pubitemid 46120195)
4. Stewart WA, Pearce R, Kirkland KE, et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010;45:1587-93.
5. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70.
6. Mesa RA. New drugs for the treatment of myelofibrosis. Curr Hematol Malig Rep 2010;5:15-21.
7. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
9. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood 2009;113:2895-901.
10. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010;116:2857-8.
11. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401-8.
12. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-203.